日本真实世界数据:≤1 cm 淋巴结阴性三阴性早期乳腺癌辅助化疗疗效
基于日本乳腺癌登记库 2004–2017 年 7362 例 pT1N0 三阴性乳腺癌患者,比较辅助化疗与未化疗的生存结局。多因素分析显示 pT1c 化疗显著改善无病生存(HR 0.61)和总生存(HR 0.57),而 pT1a 各终点均无显著获益,pT1b 无病生存与乳腺癌特异生存亦无显著获益。
要点
- pT1c N0 三阴性乳腺癌辅助化疗显著改善 DFS 和 OS
- pT1a N0 三阴性乳腺癌化疗在各终点均无显著生存获益
- ≤1 cm 三阴性乳腺癌可考虑省略化疗,需权衡毒性
核心结论
- 当代辅助化疗显著改善 pT1c N0 三阴性乳腺癌的 DFS 和 OS。
- 对于肿瘤 ≤1 cm(pT1a 和 pT1b)患者,DFS 或 BCSS 未见明确获益,省略化疗是合理选择。
研究设计与样本
- 基于日本乳腺癌学会国家临床数据库-乳腺癌登记库(NCD-BCR)2004–2017 年登记患者的回顾性队列分析。
- 共纳入 7362 例 pT1N0 三阴性乳腺癌患者,化疗组 3883 例,未化疗组 3479 例。
- 主要终点为无病生存(DFS),次要终点包括总生存(OS)和乳腺癌特异生存(BCSS),采用多因素 Cox 比例风险模型计算风险比(HR)。
主要发现
- pT1a 亚组化疗在所有终点(DFS、BCSS、OS)均无显著生存获益。
- pT1b 亚组化疗对 DFS(HR 0.88;95%CI 0.60–1.29)和 BCSS(HR 0.75;95%CI 0.30–1.88)无显著获益,OS 改善(HR 0.53;95%CI 0.29–0.96)可能反映乳腺癌特异性死亡以外的因素。
- pT1c 亚组化疗显著改善 DFS(HR 0.61;95%CI 0.51–0.73)和 OS(HR 0.57;95%CI 0.45–0.72),BCSS 无显著获益(HR 0.77;95%CI 0.56–1.06)。
临床怎么用
- pT1c N0 三阴性乳腺癌可考虑辅助化疗以改善 DFS 和 OS。
- 肿瘤 ≤1 cm(pT1a 和 pT1b)的 N0 三阴性乳腺癌,鉴于缺乏 DFS/BCSS 明确获益及治疗相关毒性,可考虑省略辅助化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of adjuvant chemotherapy for pT1N0 triple-negative breast cancer (TNBC) remains controversial, especially for tumors ≤ 1 cm. This study evaluated contemporary chemotherapy efficacy across tumor size subcategories using large-scale real-world data. METHODS: We analyzed patients with pT1 N0 TNBC registered in the National Clinical Database-Breast Cancer Registry (NCD-BCR) of the Japanese Breast Cancer Society between 2004 and 2017. The primary endpoint was disease-free survival (DFS), and secondary endpoints included overall survival (OS) and breast cancer-specific survival (BCSS). Hazard ratios (HRs) were calculated using multivariate Cox proportional hazard models. RESULTS: A total of 7362 patients were included (chemotherapy group: 3883; no-chemotherapy group: 3479). In the multivariate analysis, chemotherapy showed no significant survival benefit for the pT1a subgroup across any endpoints (DFS, BCSS, or OS). For the pT1b subgroup, chemotherapy provided no significant benefit for DFS (HR 0.88; 95% CI: 0.60-1.29) or BCSS (HR 0.75; 95% CI: 0.30-1.88); however, the observed improvement in OS (HR 0.53; 95% CI: 0.29-0.96) might reflect factors other than breast cancer-specific mortality. In contrast, for the pT1c subgroup, chemotherapy significantly improved DFS (HR 0.61; 95% CI: 0.51-0.73) and OS (HR 0.57; 95% CI: 0.45-0.72), whereas no significant benefit was observed for BCSS (HR 0.77; 95% CI: 0.56-1.06). CONCLUSIONS: While contemporary adjuvant chemotherapy significantly improves outcomes in pT1c N0 TNBC, no clear benefit for DFS or BCSS was demonstrated for patients with tumors ≤ 1 cm (T1a and T1b). Given the potential for treatment-related toxicity, the omission of chemotherapy should be considered a reasonable option for patients with TNBC ≤ 1 cm.
引用
- Koike Y, Kumamaru H, Iwamoto T, et al. Efficacy of adjuvant chemotherapy for triple-negative early breast cancer with tumor size ≤ 1 cm and node-negative from the National Clinical Database-Breast Cancer Registry in Japan. Eur J Cancer. 2026. PMID: 42475980. doi:10.1016/j.ejca.2026.116932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。